CYP2C19

# Genedrive® CYP2C19 ID Kit


## Enabling **personalised antiplatelet treatment** with rapid **genetic testing**

### Genedrive® ID Kit Procedure



**Firmly swab the patient**

**Vigorously rotate the swab to release the DNA**

**Transfer the sample**

**Reconstitute the reagents**



**Insert cartridge to start test**

**The Genedrive ID Kit includes:**

1 x Lysis buffer
1 x Buccal swab
1 x Assay cartridge
1 x Cartridge lid
1 x Transfer pipette
1 x Patient ID label

The Genedrive® CYP2C19 ID Kit is intended to be used only on the Genedrive® System to inform clinicians on an individual's CYP2C19 genotype and corresponding CYP2C19 enzyme metaboliser status, as defined by CPIC guidelines.

## Key Features

**6 ALLELES**
Ethnically diverse coverage

**REAGENTS**
Shipped and stored at room temperature

**INTEGRATED**
All you need in one compact device



**EASE-OF-USE**
1 buccal swab for the test

**RESULTS**
Diplotype and Metaboliser status

**CONNECTIVITY**
Result can be stored in Electronic Health Record

For more information scan the QR Code

For information on how to use our **CYP2C19 Collection Kit**, scan the QR Code

genedrive

# The **global burden** of stroke

## **CYP2C19 -** Personalised antiplatelet treatment

- **Clopidogrel is the first-line treatment** for secondary prevention of stroke, but at least **25% of the population (up to 56%) are resistant to clopidogrel***.
- Our CYP2C19 near-patient genetic test enables clinical targeting of optimal antiplatelet treatment, **reducing the risk of secondary stroke recurrence**.
- Provides **rapid genetic results** in just over one hour.
- Enabling clinicians to make **informed treatment decisions** in a time critical setting.

**Following a stroke, patients have a significantly higher risk of a repeated event within the first 48 hours.**

**94m**
People living with the effects of a stroke

**7m**
Deaths each year

**12m**
will have a stroke each year

## Backed by clinical evidence and guidance

CPIC Clinical Pharmacogenetics Implementation Consortium

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy 2022 Update.

**As recommended by Clinical Pharmacogenetics Implementation (CPIC)**

NICE National Institute for Health and Care Excellence

CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.

**As recommended by National Institute for Heath and Care Excellence (NICE)**

Healthcare Improvement Scotland | SHTG Advice on health technologies

Genotype testing to guide clopidogrel use after an ischaemic stroke or transient ischaemic attack (TIA)

**As recommended by American Heart Association (AHA)**

American Heart Association.

CYP2C19 Genetic Testing for OralP2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association

**As recommended by American Heart Association (AHA)**

### Intellectual Property

*References available on request. Genedrive® is a registered trademark of Genedrive Diagnostics Ltd.

CE 2962

Copyright © 2025 genedrive plc. All rights reserved. GPM-136 V4 October 2025

genedrive